US4564625A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Binary compositions of penbutolol and furosemide or piretanide
Assignee: Sanofi Aventis Deutschland GmbH
•
Filing: 1984-05-10
•
Granted: 1986-01-14
•
Expires: 2004-05-10
Abstract
Abstract Salts formed between penbutolol and furosemide or piretanide, pharmaceutical compositions containing such salts, and methods for treating diseases of the coronary and circulatory systems with such salts.
Inventors
- 👤 Roman Muschaweck
- 👤 Werner Fulberth
- 👤 Alfred Sickmuller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 04:35
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/14; C07D295/155; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/63; A61K31/635; A61P; A61P9/00; A61P9/12; C07C; C07C255/00; C07D307/00; C07D307/02; C07D307/34; C07D307/38; C07D307/52
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
22 words
A composition comprising the two components (a) furosemide or piretanide and (b) penbutolol, in a ratio by weight of (a):(b) of 1:2.
Claim 2
Dependent Claim
22 words
A composition comprising the two components (a) furosemide or piretanide and (b) penbutolol, in a ratio by weight of (a):(b) of 1:2.
Claim 3
Dependent Claim
38 words
A composition comprising the two components (a) furosemide or piretanide and (b) penbutolol in pharmaceutical dosage unit form, wherein each dosage unit comprises a mixture of 3 mg of 12 mg of piretanide and 40 mg of penbutolol.
Claim 4
Dependent Claim
38 words
A composition comprising the two components (a) furosemide or piretanide and (b) penbutolol in pharmaceutical dosage unit form, wherein each dosage unit comprises a mixture of 3 mg of 12 mg of piretanide and 40 mg of penbutolol.
Claim 5
Dependent Claim
28 words
A composition as in claim 1 in pharmaceutical dosage unit form wherein each dosage unit comprises a mixture of 20 mg of furosemide and 40 mg of penbutolol.
Claim 6
Dependent Claim
34 words
A method for treating diseases of the coronary and circulatory systems in a patient suffering therefrom, which method comprises administering to said patient a therapeutically effective amount of a composition as in claim 1.
References Cited (Backward Citations)
US3839321A
Cited
DE2227423A1
Cited
US4139633A
Cited
AT356095B
Cited
US4118587A
Cited
US4191765A
Cited
DE2638716A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-01-13 | 1989-07-15 | 1990-01-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-01-13 | 1993-07-15 | 1994-01-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-01-13 | 1997-07-15 | 1998-01-14 | $7700.00 | Window Closed / Lapsed |